Atezolizumab/nivolumabType 1 diabetes mellitus: 2 case reports

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2018年 / 1688卷 / 1期

关键词：

D O I：

10.1007/s40278-018-41670-7

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：35 / 35

相关论文

共 50 条

[31] NivolumabFulminant type 1 diabetes mellitus and type 1 diabetes mellitus: 2 case reports
Reactions Weekly, 2017, 1654 (1) : 254 - 254
[32] NivolumabType 1 diabete mellitus: case report
Reactions Weekly, 2025, 2040 (1) : 755 - 755
[33] NivolumabType 1 diabetes: case report
Reactions Weekly, 2018, 1683 (1) : 519 - 519
[34] Ipilimumab/nivolumabType 1 diabetes: case report
Reactions Weekly, 2025, 2054 (1) : 223 - 223
[35] Elasomeran/nivolumabType-1-diabetes-mellitus, ketosis and local pain: case report
Reactions Weekly, 2022, 1915 (1) : 191 - 191
[36] Ipilimumab/nivolumabType 1 diabetes: case report
Reactions Weekly, 2018, 1726 (1) : 216 - 216
[37] NivolumabType-I diabetes, pneumonitis and vitiligo: 5 case reports
Reactions Weekly, 2021, 1837 (1) : 533 - 533
[38] Ipilimumab/nivolumabType I diabetes mellitus and thyroid dysfunction: case report
Reactions Weekly, 2019, 1751 (1) : 220 - 220
[39] PasireotideDeterioration of diabetes mellitus: 2 case reports
Reactions Weekly, 2019, 1761 (1) : 292 - 292
[40] NivolumabType 1 diabetes mellitus, interstitial pneumonitis and elevated liver enzymes: 3 case report
Reactions Weekly, 2018, 1728 (1) : 273 - 273

← 1 2 3 4 5 →